These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Genetic deficiency in tissue kallikrein activity in mouse and man: effect on arteries, heart and kidney. Pizard A; Richer C; Bouby N; Picard N; Meneton P; Azizi M; Alhenc-Gelas F Biol Chem; 2008 Jun; 389(6):701-6. PubMed ID: 18627303 [TBL] [Abstract][Full Text] [Related]
5. Arterial and renal consequences of partial genetic deficiency in tissue kallikrein activity in humans. Azizi M; Boutouyrie P; Bissery A; Agharazii M; Verbeke F; Stern N; Bura-Rivière A; Laurent S; Alhenc-Gelas F; Jeunemaitre X J Clin Invest; 2005 Mar; 115(3):780-7. PubMed ID: 15765151 [TBL] [Abstract][Full Text] [Related]
6. Tissue kallikrein is required for the cardioprotective effect of cyclosporin A in myocardial ischemia in the mouse. Youcef G; Belaidi E; Waeckel L; Fazal L; Clemessy M; Vincent MP; Zadigue G; Richer C; Alhenc-Gelas F; Ovize M; Pizard A Biochem Pharmacol; 2015 Mar; 94(1):22-9. PubMed ID: 25623731 [TBL] [Abstract][Full Text] [Related]
7. Antihypertensive role of tissue kallikrein in hyperaldosteronism in the mouse. Waeckel L; Potier L; Chollet C; Taveau C; Bruneval P; Roussel R; Alhenc-Gelas F; Bouby N Endocrinology; 2012 Aug; 153(8):3886-96. PubMed ID: 22669897 [TBL] [Abstract][Full Text] [Related]
8. Tissue kallikrein is involved in the cardioprotective effect of AT1-receptor blockade in acute myocardial ischemia. Messadi-Laribi E; Griol-Charhbili V; Pizard A; Vincent MP; Heudes D; Meneton P; Alhenc-Gelas F; Richer C J Pharmacol Exp Ther; 2007 Oct; 323(1):210-6. PubMed ID: 17636004 [TBL] [Abstract][Full Text] [Related]
9. Tissue kallikrein-deficient mice display a defect in renal tubular calcium absorption. Picard N; Van Abel M; Campone C; Seiler M; Bloch-Faure M; Hoenderop JG; Loffing J; Meneton P; Bindels RJ; Paillard M; Alhenc-Gelas F; Houillier P J Am Soc Nephrol; 2005 Dec; 16(12):3602-10. PubMed ID: 16251243 [TBL] [Abstract][Full Text] [Related]
10. Tissue kallikrein deficiency and renovascular hypertension in the mouse. Griol-Charhbili V; Sabbah L; Colucci J; Vincent MP; Baudrie V; Laude D; Elghozi JL; Bruneval P; Picard N; Meneton P; Alhenc-Gelas F; Richer C Am J Physiol Regul Integr Comp Physiol; 2009 May; 296(5):R1385-91. PubMed ID: 19244588 [TBL] [Abstract][Full Text] [Related]
11. Kallikrein-kinin in stroke, cardiovascular and renal disease. Chao J; Chao L Exp Physiol; 2005 May; 90(3):291-8. PubMed ID: 15653716 [TBL] [Abstract][Full Text] [Related]
12. Role of tissue kallikrein-kininogen-kinin pathways in the cardiovascular system. Sharma JN Arch Med Res; 2006 Apr; 37(3):299-306. PubMed ID: 16513476 [TBL] [Abstract][Full Text] [Related]
14. [Kallikrein-kinin system, the kidney and arterial pressure]. Alhenc-Gelas F; Baussant T; Gardes J; Corvol P Nephrologie; 1988; 9(1):3-7. PubMed ID: 2839786 [TBL] [Abstract][Full Text] [Related]
15. The kallikrein-kinin pathways in hypertension and diabetes. Sharma JN; Narayanan P Prog Drug Res; 2014; 69():15-36. PubMed ID: 25130038 [TBL] [Abstract][Full Text] [Related]
16. Kallikrein/K1, Kinins, and ACE/Kininase II in Homeostasis and in Disease Insight From Human and Experimental Genetic Studies, Therapeutic Implication. Alhenc-Gelas F; Bouby N; Girolami JP Front Med (Lausanne); 2019; 6():136. PubMed ID: 31316987 [TBL] [Abstract][Full Text] [Related]
18. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Linz W; Wiemer G; Gohlke P; Unger T; Schölkens BA Pharmacol Rev; 1995 Mar; 47(1):25-49. PubMed ID: 7784479 [TBL] [Abstract][Full Text] [Related]
19. Role of tissue kallikrein in the cardioprotective effects of ischemic and pharmacological preconditioning in myocardial ischemia. Griol-Charhbili V; Messadi-Laribi E; Bascands JL; Heudes D; Meneton P; Giudicelli JF; Alhenc-Gelas F; Richer C FASEB J; 2005 Jul; 19(9):1172-4. PubMed ID: 15860541 [TBL] [Abstract][Full Text] [Related]
20. Renal (tissue) kallikrein-kinin system in the kidney and novel potential drugs for salt-sensitive hypertension. Katori M; Majima M Prog Drug Res; 2014; 69():59-109. PubMed ID: 25130040 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]